Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 4/2011

01.08.2011 | Research Article

Ezrin mRNA target site selection for DNAzymes using secondary structure and hybridization thermodynamics

verfasst von: YaoFei Wang, JingNan Shen, XiFu Shang, Jin Wang, JingChun Li, JunQiang Yin, ChangYe Zou

Erschienen in: Tumor Biology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Ezrin, a membrane organizer and linker between plasma membrane and cytoskeleton, is well documented to play an important role in the metastatic capacity of cancer cells especially for osteosarcoma cells. It has provided an ideal target for cancer gene therapy. RNA-cleaving 10–23 DNAzymes, consisting of a 15-nucleotide catalytical domain flanked by two target-specific complementary arms, can cleave the target mRNA at purine–pyrimidine dinucleotide effectively. In the present study, we designed and screened the target sites for 10–23 DNAzymes against ezrin mRNA by using multiple computational methods with combination of secondary structural and hybridization thermodynamic parameters. Then, we testified the activities of the DNAzymes directed against these selected target sites in vitro. Our results show that AU1751 is the most effective target site of ezrin mRNA for DNAzymes because of its ideal secondary structure and hybridization thermodynamics. So, there is a significant correlation between the multiple computational methods and the efficacy of the corresponding DNAzymes. These provide a rational, efficient way for DNAzymes selection.
Literatur
1.
Sweetnam R. Osteosarcoma. Br J Hosp Med. 1982;28:16–21.
2.
Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma. National Cancer Data Base report. Clin Orthop Relat Res. 2007;459:40–7.PubMedCrossRef
3.
Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.PubMedCrossRef
4.
Meyers PS, Heller G, Healey G, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993;11:449–53.PubMed
5.
Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol. 1998;16:3641–8.PubMed
6.
Mangeat P, Roy C, Martin M. ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol. 1999;9:187–92.PubMedCrossRef
7.
8.
9.
Khanna C, Khan J, Nguyen P, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 2001;61:3750–9.PubMed
10.
Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ. Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis. 2006;23:227–36.PubMedCrossRef
11.
Weng WH, Ahlen J, Astrom K, Lui WO, Larsson C. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res. 2005;11:6198–204.PubMedCrossRef
12.
Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10:182–6.PubMedCrossRef
13.
Sun LQ, Cairns MJ, Saravolac EG, Baker A, Gerlach WL. Catalytic nucleic acids: from lab to applications. Pharmacol Rev. 2000;52:325–47.PubMed
14.
Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci U S A. 1997;94:4262–6.PubMedCrossRef
15.
Cairns MJ, King A, Sun LQ. Optimisation of the 10–23 DNAzyme–substrate pairing interactions enhanced RNA cleavage activityat purine–cytosine target sites. Nucleic Acids Res. 2003;31:2883–9.PubMedCrossRef
16.
Vickers TA, Wyatt JR, Freier SM. Effects of RNA secondary structure on cellular antisense activity. Nucleic Acids Res. 2000;28:1340–7.PubMedCrossRef
17.
Bohula EA, Salisbury AJ, Sohail M, et al. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem. 2003;278:15991–7.PubMedCrossRef
18.
Kretschmer-Kazemi Far R, Sczakiel G. The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res. 2003;31:4417–24.PubMedCrossRef
19.
Schubert S, Grunweller A, Erdmann VA, Kurreck J. Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. J Mol Biol. 2005;348:883–93.PubMedCrossRef
20.
21.
Overhoff M, Alken M, Far RK, et al. Local RNA target structure influences siRNA efficacy: a systematic global analysis. J Mol Biol. 2005;348:871–81.PubMedCrossRef
22.
Yoshinari K, Miyagishi M, Taira K. Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res. 2004;32:691–9.PubMedCrossRef
23.
Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005;436:214–20.PubMedCrossRef
24.
Long D, Lee R, Williams P, Chan CY, Ambros V, Ding Y. Potent effect of target structure on microRNA function. Nat Struct Mol Biol. 2007;14:287–94.PubMedCrossRef
25.
Denman RB. Using RNAFOLD to predict the activity of small catalytic RNAs. Biotechniques. 1993;15:1090–5.PubMed
26.
Sczakiel G, Tabler M. Computer-aided calculation of the local folding potential of target RNA and its use for ribozyme design. Methods Mol Biol. 1997;74:11–5.PubMed
27.
James W, Cowe E. Computational approaches to the identification of ribozyme target sites. Methods Mol Biol. 1997;74:17–26.PubMed
28.
Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003;31:3406–15.PubMedCrossRef
29.
Camps-Valls G, Chalk AM, Serrano-Lopez A, Martin-Guerrero JD, Sonnhammer ELL. Profiled support vector machine for antisense oligonucleotide efficacy prediction. BMC Bioinformatics. 2004;5:135.PubMedCrossRef
30.
Chalk AM, Sonnhammer ELL. Computational antisense oligo prediction with a neural network model. Bioinformatics. 2002;18:1567–75.PubMedCrossRef
31.
Giddings MC, Shah AA, Freier S, Atkins JF, Gesteland RF, Matveeva OV. Artificial neural network prediction of antisense oligodeoxynucleotide activity. Nucleic Acids Res. 2002;30:4295–304.PubMedCrossRef
32.
Saetrom P. Predicting the efficacy of short oligonucleotides in antisense and RNAi experiments with boosted genetic programming. Bioinformatics. 2004;20:3055–63.PubMedCrossRef
33.
Thierry AR, Rahman A, Dritschilo A. Overcoming multi drug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun. 1993;190:952–60.PubMedCrossRef
34.
Jaeger JA, Turner DH, Zuker M. Improved predictions of secondary structures for RNA. Proc Natl Acad Sci U S A. 1989;86:7706–10.PubMedCrossRef
35.
Walter AE, Turner DH, Kim J, et al. Coaxial stacking of helixes enhances binding of oligoribonucleotides and improves prediction of RNA folding. Proc Natl Acad Sci U S A. 1994;91:9218–22.PubMedCrossRef
36.
37.
SantaLucia J, Allawi HT, Seneviratne PA. Improved nearest-neighbor parameters for predicting DNA duplex stability. Biochemistry. 1996;35:3555–62.PubMedCrossRef
38.
Sugimoto N, S-i N, Katoh M, et al. Thermodynamic parameters to predict stability of RNA/DNA hybrid duplexes. Biochemistry. 1995;34:11211–6.PubMedCrossRef
39.
Mathews DH, Burkard ME, Freier SM, Wyatt JR, Turner DH. Predicting oligonucleotide affinity to nucleic acid targets. RNA. 1999;5:1458–69.PubMedCrossRef
40.
Lu ZJ, Mathews DH. Efficient siRNA selection using hybridization thermodynamics. Nucleic Acids Res. 2008;36:640–7.PubMedCrossRef
41.
Lu ZX, Ye M, Yan GR, et al. Effect of EBV LMP1 targeted DNAzymes on cell proliferation and apoptosis. Cancer Gene Ther. 2005;12:646–54.CrossRef
42.
Pyle AM, Chu VT, Jankowsky E, Boudvillain M. Using DNAzymes to cut, process, and map RNA molecules for structural studies or modification. Methods Enzymol. 2000;317:140–6.PubMedCrossRef
43.
Cairns MJ, Hopkins TM, Witherington C, Wang L, Sun LQ. Target site selection for an RNA-cleaving catalytic DNA. Nat Biotechnol. 1999;17:480–6.PubMedCrossRef
44.
Mathews DH, Disney MD, Childs JL, Schroeder SJ, Zuker M, Turner DH. Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc Natl Acad Sci U S A. 2004;101:7287–92.PubMedCrossRef
45.
Xia T, SantaLucia Jr J, Burkard ME, et al. Thermodynamic parameters for an expanded nearest-neighbor model for formation of RNA duplexes with Watson–Crick pairs. Biochemistry. 1998;37:14719–35.PubMedCrossRef
46.
Torgeir H, Mohammed A, Merete TW, Eshrat B, Hans P. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res. 2002;30:1757–66.CrossRef
47.
Sohail M, Hochegger H, Klotzbucher A, Guellec RL, Hunt T, Southern EM. Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo. Nucleic Acids Res. 2001;29:2041–51.PubMedCrossRef
48.
Beale G, Hollins AJ, Benboubetra M, et al. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. J Drug Target. 2003;11:449–56.PubMedCrossRef
49.
Petch AK, Sohail M, Hughes MD, et al. Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer cells treated with scanning arraydesigned antisense oligonucleotides. Biochem Pharmacol. 2003;66:819–30.PubMedCrossRef
50.
Kurreck J, Bieber B, Jahnel R, Erdmann VA. Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. J Biol Chem. 2002;277:7099–107.PubMedCrossRef
51.
Schubert S, Gul DC, Grunert HP, Zeichhardt H, Erdmann VA, Kurreck J. RNA cleaving ‘10–23’ DNAzymes with enhanced stability and activity. Nucleic Acids Res. 2003;31:5982–92.PubMedCrossRef
52.
Schubert S, Furste JP, Werk D, et al. Gaining target access for deoxyribozymes. J Mol Biol. 2004;339:355–63.PubMedCrossRef
53.
Ho SP, Bao Y, Lesher T, et al. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol. 1998;16:59–63.PubMedCrossRef
54.
Scherer LJ, Rossi JJ. Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol. 2003;21:1457–65.PubMedCrossRef
55.
Patzel V, Steidl U, Kronenwett R, Haas R, Sczakiel G. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Res. 1999;27:4328–34.PubMedCrossRef
56.
Laptev AV, Lu Z, Colige A, Prockop DJ. Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. Biochemistry. 1994;33:11033–9.PubMedCrossRef
57.
Sczakiel G, Homann M, Rittner K. Computer-aided search for effective antisense RNA target sequences of the human immunodeficiency virus type 1. Antisense Res Dev. 1993;3:45–52.PubMed
58.
Lima WF, Monia BP, Ecker DJ, Freier SM. Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry. 1992;31:12055–61.PubMedCrossRef
59.
Matveeva O, Felden B, Audlin S, Gesteland RF, Atkins JF. A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures. Nucleic Acids Res. 1997;25:5010–6.PubMedCrossRef
60.
Ding Y, Lawrence CE. Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond. Nucleic Acids Res. 2001;29:1034–46.PubMedCrossRef
61.
Shao Y, Wu S, Chan CY, Klapper JR, Schneider E, Ding Y. A structural analysis of in vitro catalytic activities of hammerhead ribozymes. BMC Bioinformatics. 2007;30:469.CrossRef
62.
Abdelghany A, Uddin M, Wood M, Taira K, Beeson D. Design of efficient DNAzymes against muscle AChR α-subunit cRNA in vitro and in HEK293 cells. J RNAi Gene Silencing. 2005;1:88–96.
63.
Stein CA. Keeping the biotechnology of antisense in context. Nat Biotechnol. 1999;17:209–12.PubMedCrossRef
64.
Southern EM, Milner N, Mir KU. Discovering antisense reagents by hybridization of RNA to oligonucleotide arrays. Ciba Found Symp. 1997;209:38–44.PubMed
Metadaten
Titel
Ezrin mRNA target site selection for DNAzymes using secondary structure and hybridization thermodynamics
verfasst von
YaoFei Wang
JingNan Shen
XiFu Shang
Jin Wang
JingChun Li
JunQiang Yin
ChangYe Zou
Publikationsdatum
01.08.2011
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2011
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0183-4

Weitere Artikel der Ausgabe 4/2011

Tumor Biology 4/2011 Zur Ausgabe

Research Article

Estrogen receptor-alpha promoter methylation in sporadic basal-like breast cancer of Chinese women

Research Article

The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer

Research Article

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer

Research Article

Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors

Research Article

Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer

Research Article

EBV-encoded LMP1 increases nuclear β-catenin accumulation and its transcriptional activity in nasopharyngeal carcinoma

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise